Project Grant RF1NS142613
- This $2,365,042 Project Grant was awarded by the National Institute on Aging (NIA) under the Aging Research Federal Grant Program (CFDA 93.866) to conduct research on the biological underpinnings of Alzheimer's disease and related dementias (ADRD). The research aims to better characterize the interplay between biological markers of neurodegeneration, vascular, nutritional, and inflammatory systems, and their interface with social and economic factors, by leveraging cross-national comparisons...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $732,992 to Virginia Commonwealth University to elucidate the role of cholinergic degeneration in cognitive fluctuations (CF) in Lewy body dementia (LBD). The project aims to determine the association between cholinergic degeneration and CF in LBD, using neuroimaging techniques...
- This federal Project Grant award of $3,080,520.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) supports research to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias (ADRD) using resting-state functional magnetic resonance imaging (rs-fMRI) data and machine learning. The research aims to address limitations of current ADRD biomarkers by leveraging the dynamics of functional connectivity networks and accounting for heterogeneity...
- This three-year, $4.766 million project grant from the National Institute on Aging, part of the Department of Health and Human Services, aims to clarify the neuropathological, molecular, and genetic differences between Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB) through the Aging Research grant program (CFDA 93.866). The J. David Gladstone Institutes will use digital pathology, artificial intelligence, single-nuclei RNA sequencing, and spatial transcriptomics on...
- This Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) for $791,086 aims to develop computational models that can predict the presence of non-Alzheimer's disease neuropathological changes, such as Lewy body disease, TDP-43 proteinopathy, and cerebral amyloid angiopathy, in individuals with Alzheimer's disease neuropathological changes. The project will leverage data from autopsy-confirmed datasets, in vivo neuroimaging, and clinical assessments to build...
- This federal Project Grant award of $3,188,901.00 from the National Institute on Aging (CFDA 93.866 - Aging Research) aims to better understand the relationships between in-vivo biomarkers for amyloid, tau, and neurodegeneration (ATN), neuropsychiatric symptoms, vascular risk factors, and genetic risks in Alzheimer's disease. The study will leverage data from large research cohorts like the Alzheimer's Disease Neuroimaging Initiative to develop and optimize machine learning models that can...
- This Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) federal grant program, provides $2,234,905.00 in funding to The University of Iowa to support research aimed at understanding the underlying mechanisms responsible for cognitive fluctuations in Lewy body disorders (LBD). The project will use mouse models to evaluate how the accumulation of...
- The National Institute on Aging (NIA) awarded a $400,707 Project Grant (CFDA 93.866 - Aging Research) to the University of Florida to map brain lipid architecture in aging, Lewy body dementia (LBD), and T-cell therapy. The 2-year grant, running from September 1, 2024 to August 31, 2026, will utilize novel imaging mass spectrometry to generate a spatial atlas of the lipidome and identify lipid markers of disease progression in LBD. The research aims to assess lipid alterations resulting from an...
- The U.S. National Institute on Aging (NIA) awarded a $5,174,076 Cooperative Agreement grant under the Aging Research program (CFDA 93.866) to Biosensics LLC, a small business in Newton, Massachusetts. The purpose of the grant is to develop and qualify digital biomarkers to monitor motor function in individuals with Progressive Supranuclear Palsy (PSP) and Dementia with Lewy Bodies (DLB) using wearable sensor technologies. Specifically, the project will utilize Biosensics' PAMSYS and PAMSYS ULM...
- This $1,707,089 Project Grant award from the National Institute on Aging (CFDA 93.866 - Aging Research) will fund research by Northwestern University to investigate synergistic approaches for enhancing endoplasmic reticulum (ER) proteostasis, protein trafficking, and lysosomal activity as potential treatments for dementia with Lewy bodies and Parkinson's disease-dementia. The research will use patient-derived induced pluripotent stem cell neuron models and mouse models to test the effects of...
This $4,924,374 Project Grant award, with an initial term from September 1, 2025 to July 31, 2029, is provided by the National Institute on Aging (NIA) under the Aging Research federal grant program (CFDA 93.866). The award aims to validate novel biomarkers that capture the most relevant features of cognitive fluctuations in Alzheimer's disease (AD) and dementia with Lewy bodies (DLB). The project will provide a multimodal characterization of the frequency and severity of cognitive fluctuations and their longitudinal variability in the Dementia with Lewy Body Consortium (DLBC) and Alzheimer's Disease Research Centers (ADRC) cohorts. The research will utilize both clinical measures (fluctuation scales, cognitive variability) and objective digital biomarkers (actigraphy, EEG, sleep, resting-state fMRI) to evaluate the frequency and pathophysiology of cognitive fluctuations in these age-related dementia syndromes.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $4.9m | 8/21/25 |